A cross-sectional study in severe COPD patients in the Middle East and Africa (MEA): Methodology and patients’ profile
Bildiriler > Özet Bildiri
Yazarlar: Alzaabi Ashraf, Hakan Gunen, Alev GÜRGÜN, Noureddine Zidouni, Mousa Khadadah, Wael Abuharbid
Clinical Problems, , , Uluslararası, Özet Bildiri, ss PA747-PA747
DOI: 10.1183/13993003.congress-2018.pa747
Özet
Background/Aim: This study was performed to assess patient characteristics, symptoms variability and their impact on daily life activities in patients with severe stable COPD in MEA countries (Algeria, Egypt, Saudi Arabia, Kuwait, Qatar, Turkey, South Africa, and UAE). Methods: Non-interventional, cross-sectional study in patients with stable COPD (GOLD 2015, C or D categories) under maintenance treatment with spirometry performed in the last 12 months (FEV1/FVC <0.7 and FEV1 <50% predicted). Results: 3253 patients (64.1±9.5 years, 90.3% males) were enrolled between December 2015 and July 2017, mainly by pulmonologists. 36% of patients were current smokers and 25.2% reported to be exposed to biomass. Most patients (61.3%) had at least one comorbidity including hypertension (41.0%) and ischaemic heart disease (14.6%). The mean (±SD) number of exacerbations in the last 12 months was 1.7±1.5 and the mean CAT score was 20.5±7.9. The most frequent treatments were LABA + ICS (68.6% of patients), LAMA or LAMA + LABA (67.6%), and SABA or SAMA (58.8%). Breathlessness was the most common symptom over the 7 last days (84.6% of patients) followed by phlegm (73.6%), cough (75.4%), chest tightness (72.1%), and wheezing (66.9%). The severity of symptoms was heterogeneous and varied between patients: 15-33% of patients reported ‘not at all’, 26-34% reported ‘little’, 26-36% reported ‘moderate’ and 12-22% claimed the symptoms were very severe or extreme. Conclusion: Breathlessness was the most common symptom in patients with severe stable COPD in the MEA. Symptom severity was generally mild to moderate, while variable among patients. Supported by AstraZeneca